Hanyu pharmaceutical major new drug creation project "kilogram peptide drug preparation pilot test technology platform" passed the acceptance

From the research and development of Hanyu pharmaceutical in the past year, the company's R & D strength in peptide drug synthesis has attracted the attention of the market In the past more than one year, Hanyu pharmaceutical has obtained more than ten patent certificates for peptide drug preparation technology and purification method, including cetrik, atoxicban, lilalutide, etc the above people believe that the successful completion of the "11th Five Year Plan" major science and technology project - the acceptance of the kg level peptide drug preparation pilot technology platform is a affirmation of its R & D capability The preparation cost of polypeptide drugs is relatively high The construction of Hanyu pharmaceutical, a kilogram level pilot technology platform, is of great significance to reduce the cost Hanyu pharmaceutical is a national high-tech enterprise specializing in peptide drug research and development, production and sales It is the first listed company operating peptide drugs in China, with a market share of top three News extension > > strive to create the first peptide innovative drug in China 01:07, March 18, 2011 source: from generic drugs to first generic drugs to innovative drugs, China Securities Journal first occupied the domestic market and then entered the international market, which is the strategic development path planned by the management for Hanyu pharmaceutical industry Strong R & D of new preparations and production capacity of API are the "capital" for Hanyu pharmaceutical industry to develop together in domestic and foreign markets Although the company's current annual sales volume is only more than 100 million yuan, the company will take about 10% of its revenue as R & D expenses every year In addition, opening up the international market is another important development path for Hanyu pharmaceutical industry after the introduction of the first generic drugs On the one hand, the company's new production capacity and investment projects are designed in accordance with European and American standards, and its own funds are used to expand the production capacity of APIs in 2010; on the other hand, the company actively promotes the certification of products in European and American markets, and will apply for the first DMF and anda this year Hanyu pharmaceutical believes that the company's sales in the foreign market in the future will not be lower than that in China "Our long-term goal is to make Hanyu pharmaceutical become the first peptide drug enterprise in China to export to foreign market and develop a kind of innovative peptide drug enterprise." Yuan Jiancheng said that due to the limited capital and scale, the R & D cost of hundreds of millions of yuan at any time has made the domestic peptide medicine look forward to but not step forward He pointed out that, compared with the annual sales of hundreds of millions of dollars of innovative drugs launched by international manufacturers, generic drugs are still at the middle and low end of the peptide drug industry The development of innovative drugs is not only the domestic peptide industry, but also the inevitable development of the company At present, Hanyu pharmaceutical industry is actively cooperating with scientific research institutions to find potential projects.